Current Report Filing (8-k)
November 05 2019 - 11:42AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
November 5, 2019
Citius Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Nevada
(State or other jurisdiction of incorporation)
333-206903
|
|
27-3425913
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
11 Commerce Drive, 1st Floor, Cranford, NJ
|
|
07016
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including area code (908) 967-6677
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, $0.001 par value
|
|
CTXR
|
|
The Nasdaq Capital Market
|
Warrants to purchase common stock
|
|
CTXRW
|
|
The Nasdaq Capital Market
|
On November 5, 2019, we mailed to our shareholders and made
available to the investing public a corporate update on our company. A copy of the corporate update is attached as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
CITIUS PHARMACEUTICALS, INC.
|
|
|
|
|
Date: November 5, 2019
|
|
/s/ Myron Holubiak
|
|
|
|
Myron Holubiak
|
|
|
|
President and Chief Executive Officer
|
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Sep 2023 to Sep 2024